SureAdhere for Public Health
Scale patient engagement efforts through live and asynchronous video observed therapy and improve treatment outcomes through immediate follow-up with patients most in need.
SureAdhere has been clinically validated by the US Centers for Disease Control and Prevention to provide equivalent treatment outcomes to in-person directly observed therapy (DOT), without the burden or expense.
Drug-by-drug Medication Support
Detailed dosing histories combined with escalation task lists, support action logging, and side-effect tracking complete a comprehensive treatment record at every dose. Virtual care tools like two-way SMS chat and live virtual visits enable real-time feedback when patients need additional support.
Scaled Program Capacity
Focus staff resources on individuals most in need while increasing the total number of medication doses observed, saving program administration costs, and reducing dependence on paper and manual record keeping.
High Accessibility
The offline-first approach enables patients to progress through treatment at their own pace and extends access to remote support for individuals living in areas with low connectivity.
Simple app design available in multiple languages supports patients with varying language, literacy, and technical ability.
Globally Recognised
Over 350 Public Health programs across the US, Europe & Asia use SureAdhere. SureAdhere complies with US HIPAA and European GDPR data privacy regulations, and our global support team provides comprehensive service level agreements based on local time zones.
SureAdhere for TB Treatment
From 2018 to 2021, the US Centers for Disease Control and Prevention (CDC) and the New York City Department of Mental Health and Hygiene (NYC Health) conducted a randomized controlled trial (RCT) comparing eDOT to in-person DOT using the SureAdhere VOT platform for recorded eDOT. The trial, published in JAMA Open Network, demonstrated that eDOT was clinically non-inferior to in-person DOT, and reduced TB treatment burden for both patients and providers.
These trial results, along with the comprehensive VOT evidence base, informed the World Health Organization's (WHO) 2022 TB treatment guidelines. WHO’s guidelines now state that "video observed therapy may replace in-person DOT where video communication technology is available." This study also supported the CDC in updating agency TB treatment guidelines in 2023, recommending VOT as “an equivalent alternative to in-person DOT”. This milestone has allowed US health departments to widely adopt VOT as the standard of care for TB treatment in their programs.
Additional Public Health Use
HIV Treatment & Prevention
SureAdhere's self-administered dose capture functionality, along with ongoing treatment support through virtual communications, has the potential to enhance long-term health for people living with HIV and those using PrEP by helping them maintain a consistent routine, particularly during the crucial initial phase.
Real time-time data tracking with VDOT leads to better disease management and empowers patients to gain greater control over their health. Healthcare providers can effectively support and monitor patients, ensuring they receive the full benefits of DOT.
Hepatitis C
Chronic hepatitis C stands as the primary cause for liver transplants in the US (CDC 2016). To prevent delayed recovery and drug resistance caused by non-adherence to daily oral medications, we assist patients in establishing a daily medication routine. Moreover, our platform enables health professionals to effortlessly monitor Hepatitis C treatment adherence, ensuring optimal outcomes for patients.
According to recent clinical studies, the treatment time for Hepatitis C can now be reduced to around 3 months, with a remarkable 95% effectiveness..
Our Partners in Public Health
Publications & Research
Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment — United States, 2023
Feasibility and acceptability of asynchronous VOT among patients with MDR-TB”
In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial”